Reframe Health (dba Frame) is building the wrap-around services and care-navigation layer that lets existing OBGYN and fertility providers convert far more of the patients who reach them into treatment, monetizing a supply-demand gap that neither the employer-benefits managers nor the clinics themselves are structured to close. Frame sells to providers rather than employers: on the OBGYN side it credentials under the practice and bills fertility services on a roughly 25% revenue share; on the clinic side it sells reproductive endocrinologists a subscription (~$20K-$70K per year) that extends their capacity Internal (2024-06-27 note). The wedge is timing in the funnel: incumbents such as Progyny, Maven, Carrot, and Kindbody monetize once a patient is already in treatment or pregnant, whereas Frame's early-detection, triage, and coaching layer attacks the drop-out problem upstream, where only about 25-30% of patients who contact a fertility center actually start treatment Web.
Validation is concrete and provider-led. As of the 2025-09-05 call, Frame had 7 signed customers (up from the 2-3 cited earlier in diligence), including the ~$4B public primary-care group Privia and Unified Women's Health, and it had been named the number-one partner across six competing solutions in a US Fertility process in Florida Internal (2024-07-08 note). Estimated LTM revenue is roughly $1.4M Internal against blended margins near 20% today that management targets at 50-60% at scale (2024-06-27 note). StoryHouse committed $150K from Fund I via a SAFE on the 2024 seed extension; that SAFE converted in the December 2025 Seed II round (~$3.5M led by Brand Foundry Ventures) at an effective $18.4M valuation after a 20% discount to the $23M post Internal (Deal terms). Company health is currently Green.
The underlying fertility services market is large and growing steadily (secular tailwind from rising infertility rates and later family formation), but Frame's real opening is the access bottleneck within it: demand for fertility care exceeds supply roughly 7x in the US, and the drop-off between first contact and treatment leaves an estimated $66B in annual provider revenue on the table Web. Frame sells capacity and conversion into that gap rather than betting on new fertility demand.
| Player | Positioning | Funding / Stage | Edge vs. them |
|---|---|---|---|
| Reframe Health (Frame) | Provider-side wrap-around navigation and early detection; extends OBGYN and fertility-clinic capacity | Seed / ~$5.8M raised | — |
| Progyny | Public fertility-benefits manager sold to employers | Public, ~$298M Q4'24 rev Web | Frame sells to providers, not employers, and extends clinician throughput rather than routing benefits |
| Maven Clinic | Family-benefits platform (fertility, maternity, pediatrics) sold to employers | Unicorn, ~$1.35B val Web | Frame is provider-side and preventative; not a benefit paid for by the employer |
| Kindbody | Owns fertility clinics plus employer benefits | ~$1.8B val Web | Frame is asset-light and augments existing clinics rather than owning brick-and-mortar |
| Carrot Fertility | Global fertility-benefits platform for employers | Late-stage VC Web | Frame monetizes navigation and prevention, not treatment reimbursement |
Moat: distribution wins into large provider networks (Privia, Unified Women's Health, US Fertility) plus tech-enabled services breadth: Frame reports winning the Privia deal against nine other solutions Internal (2024-06-27 note), and once co-designed and live, the playbook is repeatable across a network's markets, raising switching costs.
The natural acquirers are the fertility-benefits and clinic consolidators (Progyny, Maven, Carrot, Kindbody) or the large provider networks Frame already sells into (Unified Women's Health, US Fertility, Privia), for whom Frame's conversion engine is a bolt-on. Sector M&A precedent exists: Kindbody rolled up Vios Fertility and Phosphorus Labs in 2022 Web. On StoryHouse's $150K in at an effective $18.4M, a mid-nine-figure strategic outcome would return a healthy multiple on a small Fund I check, though the outcome depends on Frame proving the at-scale margin step-up.
Follow-up call with Jessica (with Matthew and Miles) on financial projections, the current raise, and customer build.
Frame <> StoryHouse follow-up, Thu 04 Sept 25, with Jessica Bell van der Wal, matthew@storyhousevc.com, miles@storyhousevc.com, and Corey van der Wal.
Financial projections & funding strategy: default alive in early 2027 with a 6% EBITDA margin in the current model; with a 42% gross margin they could reach default alive mid-2026, but that would require very lean operations with the current 7.5 FTEs and would mean decreased revenue acceleration. Fundraising range of $1-3M on the existing SAFE (19 post): $1M for steady state servicing existing contracts, $2M to lean into opportunities with moderate acceleration, $3M to invest in core technology and pipeline acceleration. Early in the process, still TBD on interest; KLI Capital institutional investor discussed; one original angel committed to super pro rata.
Customer base growth & revenue build: now 7 signed customers (up from 2-3 previously mentioned), all on slides signed and existing, some rolling out slowly and others at full scale, including Privia and other major healthcare providers. Revenue model builds over time with large per-customer potential barely tapped; product mix shifting toward higher-margin SaaS network products.
Fundraising feedback: Matt's key recommendation is to add a building-block analysis to the pitch, showing unit economics for individual customers first, then compounding multiple customers with overhead, separating direct from indirect costs to make the case to finance-focused investors. Current deck is strong on concept but light on the operational "how." Potential for customer co-investment partnerships, with pharma partners more open to upfront payments than providers, and a claimed 3x ROI in 3 months that could support upfront-payment requests.
Next steps: finish existing investor conversations by end of week, start new investor meetings the following week in a tiered approach, and use the StoryHouse database for warm-intro research. Action items: finalize model numbers, create building-block slides, share investor target list, and explore customer co-investment.
Diligence call covering the Unified Women's Health contract, the US Fertility process, provider economics, and StoryHouse's check size.
Positive customer testimonials, including provider testimonial audio. Frame is contracting with Unified Women's Health, which is about 4x the women's-health business of Privia and which acquired a large fertility clinic group; this is their first opportunity with both under one umbrella (leadership support from Bob Legalia). Frame spent a full day onsite and is working on implementation for one region (New Jersey) as it did with Privia, to prove the model in one geography before expanding. Difficulties will be workflow changes, though a PE-backed organization is incentivized to drive behavior change; the two sides are moving onto one EMR.
On economics, the OBGYN model is revenue share and the clinic model is subscription ($20K-$70K per physician); for Unified it is a bit of both, and Frame sells the way customers prefer to buy to move contracts. On the US Fertility Florida process, Frame was told it was the number-one partner across six companies; half of the others are apps with no services element, and the rest touch only one part of the equation, so Frame's technology-enabled breadth was the differentiator.
Revenue model jumps ~5x from 2024 to 2025, driven primarily by success with existing customers (expanding regions or specialties) rather than new logos, with Unified and IVI RMA each ramping based on rollout discussions; the model is probability-weighted to be conservative. Frame had ~1,100 cases; pricing is based on historical reimbursement rates, with ~75% of the ~$170 going to Frame and 25% to Privia. Sales and BD are primarily Jessica plus a consultant; there was one involuntary turnover on the account-management side. Runway is ~9 months now, with ~18 months added after the round. An investor committed the morning of the call; the raise is about halfway there, with a few later-stage investors that could put in $1-2M. StoryHouse's investment was discussed at $150K-$300K, pencil in $200-250K. Next step: a reference interaction with one of the providers.
Diligence call with the founders on team, the wrap-around model, business model, revenue traction, and the financing terms.
Team: Corey (Pomona '07, Economics; Kaiser and early-stage healthcare startups) and Jessica (sold into employers and payers) went through the fertility journey together. Frame is focused on the clinician shortage and lack of fertility expertise (OBGYNs get only ~2 weeks of fertility training), building a wrap-around services model that makes the ~1,200 fertility specialists more efficient and extends physicians' care while making them money.
Business model: sells to providers. Privia is a ~$4B public company with ~4,400 providers tracking to ~$1M this year, with $4-5M expected across current and contracted customers. GTM covers OBGYNs (one product; Frame credentials under them, bills for services, and takes ~25% revenue share) and fertility clinics (reproductive endocrinologists; subscription, currently ~75% of the mix, expected to flip toward revenue share over time). Even in states with mandated fertility coverage, drop-out is ~50% (worse, ~80%, in non-mandated states); Frame sees ~80% conversion of referred patients. Four products: Extend, Connect, Prepare, Support. Coaching is one online visit plus texting delivered by certified fertility coaches; blended margins are ~20% today, targeted at 50-60% at scale.
Clinic pricing is ~$20K-$70K per year (~$45K average). Long-term vision is to become standard of care as far upstream as possible, with expansion into pregnancy, postpartum, and nutrition support. On defensibility, many partners lack virtual-care and technology DNA, and Frame won the big Privia deal against nine other solutions. Five-to-ten-year revenue view: ~$50M ARR from signed or contracting customers plus ~$40M from prospective ones.
Financing: raising $3M by reopening the prior round's terms ($14M pre-money; the prior round raised $2.5M, led by Brand Foundry), to hire ahead of customer onboarding; had closed ~$500K from insiders with potentially another ~$500K, targeting a July close. Summary (deal owner): strong founders who have made good progress on Privia and the business model, though revenue is slow to ramp; terms are the same as before but the business is more attractive; skeptical of expansion beyond fertility, and the business could be materially affected by a Trump presidency.